WO1998008529A1 - Method of inhibiting fibrosis with a somatostatin agonist - Google Patents
Method of inhibiting fibrosis with a somatostatin agonist Download PDFInfo
- Publication number
- WO1998008529A1 WO1998008529A1 PCT/US1997/014154 US9714154W WO9808529A1 WO 1998008529 A1 WO1998008529 A1 WO 1998008529A1 US 9714154 W US9714154 W US 9714154W WO 9808529 A1 WO9808529 A1 WO 9808529A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- phe
- thr
- trp
- lys
- cys
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- Tissue comprises organized cellular groups that are attached to an extracellular matrix and are surrounded by a network of blood vessels.
- Fibrosis is an abnormal accumulation of a collagen matrix following injury or inflammation which alters the structure and function of various tissues. Irrespective of location, the major pathology of fibrosis involves an excessive deposition of a collagen matrix which replaces the normal tissue at that site. Progressive fibrosis in the kidney, liver, lung, heart, bone or bone marrow, and skin is a major cause of death and suffering. See, e.g., Border, et al. , New Engl . J. Med. 331:1286 (1994) . Development of fibrosis has been linked to the overexpression and over-production of TGF- ⁇ in numerous tissues and fibrotic disease states (see Border et al . , N Engl J Med 1994, pp. 1286-92).
- the present invention relates to a method of treating fibrosis in a patient (e.g., a mammal such as a human) .
- the method includes the step of administering a therapeutically effective amount of somatostatin or a somatostatin agonist to said patient.
- the somatostatin or somatostatin agonist may be administered orally, topically, parenterally, e.g., administered intravenously, subcutaneously, or by implantation of a sustained release formulation.
- Fibrosis is the abnormal accumulation of an extracellular matrix (e.g., collagen) in tissue.
- the fibrosis may be located: in the kidney, for example, fibrosis as observed in glomerulonenephritis, diabetic nephropathy) , allograft rejection, and HIV nephropathy; in the liver, for example, cirrhosis, and veno-occlusive disease; in the lung, for example, idiopathic fibrosis; in the skin, for example, systemic sclerosis, keloids, scars, and eosinophilia-myalgia syndrome; in the central nervous system, for example.
- a fibrotic disorder may be induced by a number of causes including: chemotherapy, for example pulmonary fibrosis resulting from bleo ycin, chlorambucil, cyclophsphamide, methotrexate, mustine, or procarbazine treatment; radiation exposure whether accidental or purposeful as in radiation therapy, for example, interstitial lung disease (ILD) resulting from radiation; environmental or industrial factors or pollutants such as chemicals, fumes, metals, vapors, gases, etc. (e.g.
- ILD resulting from asbestos or coal dust a drug or combination of drugs, for example, antibiotics (e.g. penicillins, sulfonamides, etc.), cardiovascular drugs (e.g. hydralazine, beta blockers, etc.), CNS drugs (phenytoin, chlorpromazine, etc.) anti-inflammatory drugs (e.g. gold salts, phenylbutazone, etc.), etc.
- antibiotics e.g. penicillins, sulfonamides, etc.
- cardiovascular drugs e.g. hydralazine, beta blockers, etc.
- CNS drugs phenytoin, chlorpromazine, etc.
- anti-inflammatory drugs e.g. gold salts, phenylbutazone, etc.
- this invention provides a method of inhibiting fibrosis in a patient, said method comprising administering a therapeutically effective amount of somatostatin or a somatostatin agonist to said patient; a method which is preferred of the foregoing method is wherein said method comprises administering a therapeutically effective amount of a somatostatin agonist to said patient.
- this invention provides a method of inhibiting fibrosis in a patient which comprises administering to the patient a therapeutically effective amount of a somatostatin agonist wherein the fibrosis which is inhibited is in the: kidney wherein the fibrotic disorder inhibited in the kidney is preferably glomerulonephritis, diabetic nephropathy, allograft rejection or HIV nephropathy, lung wherein the fibrotic disorder inhibited in the lung is preferably idiopathic fibrosis or autoimmune fibrosis, liver wherein the fibrotic disorder inhibited in the liver is preferably cirrhosis or veno-occlusive disease, skin wherein the fibrotic disorder inhibited in the skin is preferably systemic sclerosis, keloids, scars or eosinophilia-myalgia syndrome, central nervous system wherein the fibrotic disorder inhibited in the central nervous system is preferably intraocular fibrosis, bone or bone marrow,
- this invention provides a method of inhibiting fibrosis in a patient which comprises administering to the patient a therapeutically effective amount of a somatostatin agonist wherein the fibrosis is induced by chemotherapy and preferably the fibrosis inhibited is in the kidney, lung, liver, skin, central nervous system, bone or bone marrow, cardiovascular system, an endocrine organ or gastrointestinal system.
- a somatostatin agonist wherein the fibrosis is induced by chemotherapy and preferably the fibrosis inhibited is in the kidney, lung, liver, skin, central nervous system, bone or bone marrow, cardiovascular system, an endocrine organ or gastrointestinal system.
- this invention provides a method of inhibiting fibrosis in a patient which comprises administering to the patient a therapeutically effective amount of a somatostatin agonist wherein the fibrosis is induced by radiation and preferably the fibrosis inhibited is in the kidney, lung, liver, skin, central nervous system, bone or bone marrow, cardiovascular system, an endocrine organ or gastrointestinal system.
- a somatostatin agonist wherein the fibrosis is induced by radiation and preferably the fibrosis inhibited is in the kidney, lung, liver, skin, central nervous system, bone or bone marrow, cardiovascular system, an endocrine organ or gastrointestinal system.
- this invention provides a method of inhibiting fibrosis in a patient which comprises administering to the patient a therapeutically effective amount of a somatostatin agonist wherein the fibrosis is induced by a drug or combination of drugs and preferably the fibrosis inhibited is in the kidney, lung, liver, skin, central nervous system, bone or bone marrow, cardiovascular system, an endocrine organ or gastrointestinal system.
- a somatostatin agonist wherein the fibrosis is induced by a drug or combination of drugs and preferably the fibrosis inhibited is in the kidney, lung, liver, skin, central nervous system, bone or bone marrow, cardiovascular system, an endocrine organ or gastrointestinal system.
- this invention provides a method of inhibiting fibrosis in a patient which comprises administering to the patient a therapeutically effective amount of a somatostatin agonist wherein the fibrosis is induced by a disease state and preferably the fibrosis inhibited is in the kidney, lung, liver, skin, central nervous system, bone or bone marrow, cardiovascular system, an endocrine organ or gastrointestinal system.
- a somatostatin agonist wherein the fibrosis is induced by a disease state and preferably the fibrosis inhibited is in the kidney, lung, liver, skin, central nervous system, bone or bone marrow, cardiovascular system, an endocrine organ or gastrointestinal system.
- this invention provides a method of inhibiting fibrosis in a patient which comprises administering to the patient a therapeutically effective amount of a somatostatin agonist wherein the fibrosis is induced by an environmental or industrial factor and preferably the fibrosis inhibited is in the kidney, lung, liver, skin, central nervous system, bone or bone marrow, cardiovascular system, an endocrine organ or gastrointestinal system.
- a somatostatin agonist wherein the fibrosis is induced by an environmental or industrial factor and preferably the fibrosis inhibited is in the kidney, lung, liver, skin, central nervous system, bone or bone marrow, cardiovascular system, an endocrine organ or gastrointestinal system.
- this invention provides a method of inhibiting fibrosis in a patient which comprises administering to the patient a therapeutically effective amount of a somatostatin agonist wherein the fibrosis is induced by an immune response by the patient and preferably the fibrosis inhibited is in the kidney, lung, liver, skin, central nervous system, bone or bone marrow, cardiovascular system, an endocrine organ or gastrointestinal system.
- a somatostatin agonist wherein the fibrosis is induced by an immune response by the patient and preferably the fibrosis inhibited is in the kidney, lung, liver, skin, central nervous system, bone or bone marrow, cardiovascular system, an endocrine organ or gastrointestinal system.
- this invention provides a method of inhibiting fibrosis in a patient which comprises administering to the patient a therapeutically effective amount of a somatostatin agonist wherein the fibrosis is induced by a wound and preferably the fibrosis inhibited is in the kidney, lung, liver, skin, central nervous system, bone or bone marrow, cardiovascular system, an endocrine organ or gastrointestinal system.
- a somatostatin agonist wherein the fibrosis is induced by a wound and preferably the fibrosis inhibited is in the kidney, lung, liver, skin, central nervous system, bone or bone marrow, cardiovascular system, an endocrine organ or gastrointestinal system.
- this invention provides a method of inhibiting fibrosis in a patient which comprises administering to the patient a therapeutically effective amount of a somatostatin agonist wherein the somatostatin agonist has a higher binding affinity for human somatostatin sub-type receptor 1 than the other human somatostatin subtype receptors, for human somatostatin sub-type receptor 2 than the other human somatostatin sub-type receptors, for human somatostatin sub-type receptor 3 than the other human somatostatin sub-type receptors for human somatostatin sub- type receptor 4 than the other human somatostatin sub-type receptors, or for human somatostatin sub-type receptor 5 than the other human somatostatin sub-type receptors; or wherein the somatostatin agonist has a higher binding affinity for two or more of human somatostatin receptor sub-types e.g., 1, 2, 3, 4 and/or 5.
- a somatostatin agonist has a higher binding affinity
- this invention provides a method of inhibiting fibrosis in a patient which comprises administering to the patient a therapeutically effective amount of a somatostatin agonist wherein the somatostatin agonist is
- a 1 is a D- or L- isomer of Ala, Leu, lie, Val, Nle, Thr, Ser, ⁇ -Nal, ⁇ -Pal, Trp, Phe, 2 , -dichloro-Phe, pentafluoro-Phe, p-X-Phe, or o-X-Phe;
- a 2 is Ala, Leu, lie, Val, Nle, Phe, ⁇ -Nal, pyridyl- Ala, Trp, 2, -dichloro-Phe, pentafluoro-Phe, o-X-Phe, or p-X- Phe;
- a 3 is pyridyl-Ala, Trp, Phe, ⁇ -Nal, 2, -dichloro-Phe, pentafluoro-Phe, o-X-Phe, or p-X-Phe;
- a 6 is Val, Ala, Leu, lie, Nle, Thr, Abu, or Ser;
- a 7 is Ala, Leu, He, Val, Nle, Phe, ⁇ -Nal, pyridyl-
- a 8 is a D- or L-isomer of Ala, Leu, He, Val, Nle, Thr, Ser, Phe, ⁇ -Nal, pyridyl-Ala, Trp, 2, -dichloro-Phe, pentafluoro-Phe, p-X-Phe, or o-X-Phe; wherein X for each occurrence is independently selected from the group consisting of CH 3 , Cl, Br, F, OH, OCH 3 and N0 2 ; each Ri and R 2 , independently, is H, lower acyl or lower alkyl; and R 3 is OH or NH 2 ; provided that at least one of A 1 and A 8 and one of A 2 and A 7 must be an aromatic amino acid; and further provided that A 1 , A 2 , A 7 and A 8 cannot all be aromatic amino acids.
- a method of inhibiting fibrosis in a patient which comprises administering to the patient a therapeutically effective amount of a somatostatin agonist wherein the somatostatin agonist is
- a method of inhibiting fibrosis in a patient which comprises administering to the patient a therapeutically effective amount of a somatostatin agonist wherein the somatostatin agonist is
- a method of inhibiting fibrosis in a patient which comprises administering to the patient a therapeutically effective amount of a somatostatin agonist wherein the somatostatin agonist is D- ⁇ -Nal-Cys-Tyr-D-Trp- Lys-Thr-Cys-Thr-NH 2 , H-Cys-Phe-Phe-D-Trp-Lys-Thr-Phe-Cys-NH 2 ,
- this invention provides a method of inhibiting overexpression of TGF- ⁇ which comprises administering to a subject an effective amount of somatostatin, somatostatin agonist or a pharmaceutically acceptable salt thereof; preferred of this method is where a somatostatin agonist is administered; a preferred method of the immediately foregoing method is wherein the somatostatin agonist has a higher binding affinity for human somatostatin sub-type receptor 1 than the other human somatostatin sub- type receptors, human somatostatin sub-type receptor 2 than the other human somatostatin sub-type receptors, human somatostatin sub-type receptor 3 than the other human somatostatin sub-type receptors, human somatostatin sub-type receptor 4 than the other human somatostatin sub-type receptors or human somatostatin sub-type receptor 5 than the other human somatostatin sub-type receptors; or wherein the somatostatin agonist has a higher binding affinity for two or more of
- this invention provides a method of inhibiting overexpression of TGF- ⁇ which comprises administering to a subject an effective amount of a somatostatin agonist wherein the somatostatin agonist is Ri
- a 1 is a D- or L- isomer of Ala, Leu, He, Val, Nle, Thr, Ser, ⁇ -Nal, ⁇ -Pal, Trp, Phe, 2, 4-dichloro-Phe, pentafluoro- Phe, p-X-Phe, or o-X-Phe;
- a 2 is Ala, Leu, He, Val, Nle, Phe, ⁇ -Nal, pyridyl-Ala, Trp, 2, -dichloro-Phe, pentafluoro-Phe, o-X-Phe, or p-X-Phe;
- a 3 is pyridyl-Ala, Trp, Phe, ⁇ -Nal, 2 , 4-dichloro-Phe, pentafluoro-Phe, o-X-Phe, or p-X-Phe;
- a 6 is Val, Ala, Leu, He, Nle, Thr, Abu, or Ser;
- a 7 is Ala, Leu, He, Val, Nle, Phe, ⁇ -Nal, pyridyl-Ala, Trp, 2, 4-dichloro-Phe, pentafluoro-Phe, o-X-Phe, or p-X-Phe;
- a 8 is a D- or L-isomer of Ala, Leu, He, Val, Nle, Thr, Ser, Phe, ⁇ -Nal, pyridyl-Ala, Trp, 2 , -dichloro-Phe, pentafluoro-Phe, p-X-Phe, or o-X-Phe; wherein X for each occurrence is independently selected from the group consisting of CH 3 , Cl, Br, F, OH, OCH 3 and N0 2 ; each Ri and R 2 , independently, is H, lower acyl or lower alkyl; and R 3 is OH or NH 2 ; provided that at least one of A 1 and A
- this invention provides a method of inhibiting overexpression of TGF- ⁇ which comprises administering to a subject an effective amount of somatostatin agonist wherein the somatostatin agonist is
- this invention provides a method of inhibiting overexpression of TGF- ⁇ which comprises administering to a subject an effective amount of somatostatin agonist wherein the somatostatin agonist is D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys- ⁇ -Nal-NH 2 ; D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Cys- ⁇ -Nal-NH 2 ; D- ⁇ -Nal-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH 2 ;
- this invention provides a method of inhibiting overexpression of TGF- ⁇ which comprises administering to a subject an effective amount of somatostatin agonist or a pharmaceutically acceptable salt thereof wherein the somatostatin agonist or a pharmaceutically acceptable salt thereof is D- ⁇ -Nal-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-NH 2 , H-Cys- Phe-Phe-D-Trp-Lys-Thr-Phe-Cys-NH 2 ,
- this invention provides a method wherein it is preferred that of each of the methods described above that the somatostatin agonist is administered parenterally and more preferably that the somatostatin agonist administered parenterally is administered in a sustained release formulation. It is also preferred that of each of the methods described above that the somatostatin agonist or pharmaceutically acceptable salt thereof is administered orally or topically. Each of the foregoing methods is preferred.
- Still another aspect of the present invention provides a pharmaceutical composition useful for inhibiting fibrosis in a patient which comprises a pharmaceutically acceptable carrier and an effective amount of somatostatin, somatostatin agonist or a pharmaceutically acceptable salt thereof, preferred of the immediately foregoing pharmaceutical composition is a pharmaceutical composition which comprises a somatostatin agonist or a pharmaceutically acceptable salt thereof.
- Still another aspect of the present invention provides a pharmaceutical composition useful for inhibiting overexpression of TGF- ⁇ which comprises a pharmaceutically acceptable carrier and an effective amount of somatostatin, somatostatin agonist or a pharmaceutically acceptable salt thereof, preferred of the immediately foregoing pharmaceutical composition is a pharmaceutical composition which comprises a somatostatin agonist or a pharmaceutically acceptable salt thereof.
- somatostatin agonist will be defined below.
- a therapeutically effective amount depends upon the condition being treated, treatment regimen, the route of administration chosen, and the specific activity of the compound used and ultimately will be decided by the attending physician or veterinarian.
- the somatostatin agonist is administered to the patient until the fibrotic process is arrested and/or is reversed.
- the somatostatin agonist is administered for the lifetime of the patient.
- the somatostatin agonist is administered prior to the event which initiates the fibrotic process (e.g., prior to chemotherapy or exposure to radiation such as in radiation therapy) .
- Somatostatin or a somatostatin agonist may be injected parenterally, e.g., intravenously, into the bloodstream of the subject being treated.
- the route such as subcutaneous, intramuscular, intraperitoneal, enterally, transdermally, transmucously, sustained released polymer compositions (e.g., a lactic acid polymer or lactic-glycolic acid copolymer microparticle or implant), profusion, nasal, oral, topical, vaginal, rectal, nasal, sublingual, etc., will vary with the condition being treated and the activity and bioavailability of the somatostatin agonist being used.
- the dosage of active ingredient administered in a method of this invention may be varied; however, it is necessary that the amount of the active ingredient be such that a suitable dosage form is obtained.
- the selected dosage depends upon the desired therapeutic effect, on the route of administration, and on the duration of the treatment. Generally, dosage levels of between 0.000001 to 100 mg/kg of body weight daily are administered to humans and other animals, e.g., mammals. A preferred dosage range is 0.01 to 5.0 mg/kg of body weight daily which can be administered as a single dose or divided into multiple doses.
- the somatostatin agonist While it is possible for the somatostatin agonist to be administered as the pure or substantially pure compound, it may also be presented as a pharmaceutical formulation or preparation.
- the formulations to be used in the present invention, for both humans and animals, comprise any of the somatostatin agonists to be described below, together with one or more pharmaceutically acceptable carriers thereof, and optionally other therapeutic ingredients.
- the carrier must be "acceptable" in the sense of being compatible with the active ingredient ( s) of the formulation (e.g., capable of stabilizing peptides) and not deleterious to the subject to be treated.
- the formulation should not include oxidizing agents or other substances with which peptides are known to be incompatible.
- oxidizing agents or other substances with which peptides are known to be incompatible For example, somatostatin agonists in the cyclized form (e.g., internal cysteine disulfide bond) are oxidized; thus, the presence of reducing agents as excipients could lead to an opening of the cysteine disulfide bridge.
- highly oxidative conditions can lead to the formation of cysteine sulfoxide and to the oxidation of tryptophane. Consequently, it is important to carefully select the excipient. pH is another key factor, and it may be necessary to buffer the product under slightly acidic conditions (pH 5 to 6) .
- formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active ingredient (s) into association with the carrier which constitutes one or more accessory ingredients .
- the formulations for tablets or powders are prepared by uniformly and intimately blending the active ingredient with finely divided solid carriers, and then, if necessary, as in the case of tablets, forming the product into the desired shape and size.
- Formulations suitable for parenteral (e.g., intravenous) administration conveniently comprise sterile aqueous solutions of the active ingredient (s) .
- the solutions are isotonic with the blood of the subject to be treated.
- Such formulations may be conveniently prepared by dissolving active ingredient ( s) in a solvent comprising water to produce an aqueous solution, and rendering said solution sterile.
- the formulation may be presented in unit or multi-dose containers, for example, sealed ampoules or vials.
- compositions suitable for sustained release parenteral administrations are also well known in the art. See, e.g., U.S. Patent Nos. 3,773,919 and 4,767,628, the teachings of which are incorporated herein by reference, and PCT Publication No. WO 94/15587.
- Compositions for rectal or vaginal administration are preferably suppositories which may contain, in addition to the active substance, excipients such as coca butter or a suppository wax.
- compositions for nasal or sublingual administration are also prepared with standard excipients well known in the art.
- topical administration they are best used in the form of solutions, creams, salves, lotions, ointments and the like .
- the somatostatin or somatostatin agonist may also be administered with known initiators (e.g., chemotherapeutics) of the fibrotic process to ameliorate fibrosis or to prevent the initiation of fibrosis.
- known initiators e.g., chemotherapeutics
- ⁇ -Nal ⁇ -naphthylalanine
- ⁇ -Pal ⁇ -pyridylalanine
- hArg(Bu) N-guanidino- (butyl) -homoarginine
- Lys(iPr) N e -isopropyllysine
- AChxAla aminocyclohexylalanine
- Trp(F) 5-fluoro-tryptophan
- Trp(N0 2 ) 5-nitro-tryptophan
- the fibrosis which is inhibited can be located in various parts of the body and can be of a particular kind, for example, the fibrosis may be located: in the kidney, for example, fibrosis as observed in glomerulonenephritis (see Yoshioka et al.. Lab Invest 1993; 68: 154-63), diabetic nephropathy (see Yamamoto et al .
- a fibrotic disorder may be induced by a number of causes including : chemotherapy, for example, pulmonary fibrosis resulting from bleomycin, chlorambucil, cyclophsphamide, methotrexate, mustine, or procarbazine treatment (see Key Facts in Oncology by Lilly, Drug Therapy, p.11, 1994); radiation exposure whether accidental or purposeful as in radiation therapy, for example, interstitial lung disease (ILD) resulting from radiation (see Cecil Textbook of Medicine, 19 th Edition, edited by James B. Wyngaarden, Lloyd H. Smith, Jr., and J. Claude Bennet, Chapter 60, Table 60-5, p.
- chemotherapy for example, pulmonary fibrosis resulting from bleomycin, chlorambucil, cyclophsphamide, methotrexate, mustine, or procarbazine treatment (see Key Facts in Oncology by Lilly, Drug Therapy, p.11, 1994); radiation exposure whether accidental or purposeful as in radiation therapy,
- ILD intracranial pressure
- an immune reaction disorder for example, chronic graft- vs-host disease with dermal fibrosis, (see Fibrotic Skin Diseases, Editorial, J. Uitto and S.
- SRIF has both a 14 amino acid isoform (somatostatin-14 ) and a 28 amino acid isoform (somatostatin-28 ) . See Wilson, J. &
- somatostatin agonists compounds that are short peptides modified by organic moieties and non-peptides, such as organic molecules that do not have an art-recognized amino acid as part of its structure, that bind to somatostatin receptor (s) are also within the meaning of "somatostatin agonists".
- the somatostatin agonist may be a SSTR-1 agonist, SSTR- 2 agonist, SSTR-3 agonist, SSTR-4 agonist of a SSTR-5 agonist.
- the somatostatin agonist is an SSTR-2 agonist or an SSTR-5 agonist.
- an “SSTR-2 agonist” or an “SSTR-5 agonist” is a compound which (1) has a high affinity (e.g., Ki of less than 1 :M or, preferably, of less than 10 nM) for the SSTR-2 or SSTR-5, respectively (as defined by the receptor binding assay described below), and (2) inhibits the formation of fibrosis
- the somatostatin agonist may also be selective for a particular somatostatin receptor, e.g., have a higher binding affinity for a particular somatostatin receptor subtype.
- the somatostatin receptor is an SSTR-2 or SSTR-5 selective agonist.
- Somatostatin agonists which can be used to practice the therapeutic method of the present invention include, but are not limited to, those covered by formulae or those specifically recited in the publications set forth below, all of which are hereby incorporated by reference.
- somatostatin agonists include, but are not limited to, the following somatostatin analogs and pharmaceutically acceptable salt thereof which are disclosed in the above-cited references:
- H-hArg (hexyl) 2 -Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH 2 ; Ac-D-hArg (Et) 2 -Gly-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NHEt;
- each amino acid residue represents the structure of -NH-C (R) H-CO-, in which R is the side chain (e.g., CH 3 for Ala) except for Thr-ol which means -NH-CH (CH (CH 3 ) OH) -CH 2 -OH and Pro which means prolinyl.
- Lines between amino acid residues represent peptide bonds which join the amino acids.
- the amino acid residue is optically active, it is the L-form configuration that is intended unless D-form is expressly designated.
- a disulfide bridge is formed between two Cys residues; however, it is not shown.
- a 1 is a D- or L- isomer of Ala, Leu, He, Val, Nle, Thr, Ser, ⁇ -Nal, ⁇ -Pal, Trp, Phe, 2 , 4-dichloro-Phe, pentafluoro-Phe, p-X-Phe, or o-X-Phe;
- a 2 is Ala, Leu, He, Val, Nle, Phe, ⁇ -Nal, pyridyl- Ala, Trp, 2 , -dichloro-Phe, pentafluoro-Phe, o-X-Phe, or p-X- Phe;
- a 3 is pyridyl-Ala, Trp, Phe, ⁇ -Nal, 2, 4-dichloro-Phe, pentafluoro-Phe, o-X-Phe, or p-X-Phe;
- a 6 is Val, Ala, Leu, He, Nle, Thr, Abu, or Ser;
- a 7 is Ala, Leu, He, Val, Nle, Phe, ⁇ -Nal, pyridyl-
- a 8 is a D- or L-isomer of Ala, Leu, He, Val, Nle, Thr, Ser, Phe, ⁇ -Nal, pyridyl-Ala, Trp, 2, 4-dichloro-Phe, pentafluoro-Phe, p-X-Phe, or o-X-Phe; each Ri and R 2 , independently, is H, lower acyl or lower alkyl; and R 3 is OH or NH 2 ; provided that at least one of A 1 and A 8 and one of A 2 and A 7 must be an aromatic amino acid; and further provided that A 1 , A 2 , A 7 and A 8 cannot all be aromatic amino acids.
- linear agonists to be used in the method of this invention include:
- one or more chemical moieties e.g., a sugar derivative, mono- or poly-hydroxy C 2 - 12 alkyl, mono or poly- hydroxy C 2 -12 acyl groups, or a piperazine derivative
- a somatostatin agonist e.g., to the N-terminus amino acid.
- a somatostatin agonist which contain N- terminal chemical substitutions are:
- Synthesis of short amino acid sequences is well established in the peptide art.
- synthesis of D- Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH 2 can be synthesized by following the protocol set forth in U.S. Patent No. 4,853,371 and synthesis of H-D-Phe-Phe-Phe-D-Trp- Lys-Thr-Phe-Thr-NH 2 , described above, can be achieved by following the protocol set forth in Example I of European Patent Application 0 395 417 Al .
- somatostatin agonists with a substituted N-terminus can be achieved, for example, by following the protocol set forth in WO 88/02756, European Patent Application No. 0 329 295, and PCT Publication No. WO 94/04752.
- Somatostatin Receptor Binding Assays The human SSTR-1, SSTR-2, SSTR-3, SSTR-4, and SSTR-5 cDNA clones have been described (SSTR-1 and SSTR-2 in Yamada, Y., et al., Proc. Natl. Acad. Sci. USA., 89:251-255 (1992); SSTR-3 in Yamada, et al . , Mol. Endocrinol .
- mammalian expression vectors include pcDNAl/Amp (Invitrogen, Sandlesy, CA) .
- the expression plasmids were introduced into the suitable bacterial host, E. Coli HB101 (Stratagene, La Jolla, CA) and plasmid DNAs, for transfection, were prepared on Cesium Chloride gradients.
- CHO-K1 ovary, Chinese hamster cells were obtained from ATCC (ATCC No. CCL 61) . The cells were grown and maintained in Ham's F12 media (Gibco BRL, Grand Island, NY) supplemented with 10% fetal bovine serum under standard tissue culture conditions. For trans ection, the cells were seeded at a density 1 x 10 6 /60-cm plate (Baxter Scientific Products, McGaw Park, IL.). DNA mediated transfection was carried out using the calcium phosphate co-precipitation method (Ausubel, F.M., et al . , Current Protocols in Molecular Biology, John Wiley & Sons, 1987).
- the plasmid pRSV-neo (ATCC; ATCC No. 37198) was included as a selectable marker at 1/10 the concentration of the expression plasmid.
- CHO-K1 clonal cell lines that have stably inherited the transfected DNA were selected for growth in Ham's F12 media containing 10% fetal bovine serum and 0.5mg/ml of G418 (Sigma). The cells were ring-cloned and expanded in the same media for analysis.
- Transfected cell lines expressing the human SSTR receptors were clonally expanded in culture and used in the following SSTR binding protocol.
- Crude membranes were prepared by homogenization of the transfected cells in 20 ml of ice-cold 50 mM Tris-HCl with a tissue homogenizer (setting 6, 15 sec) . Buffer was added to obtain a final volume of 40 ml, and the homogenate was centrifuged in a Sorval® SS-34 rotor (Sorval, Newtown, Connecticut) at 39,000 g for 10 min at 0-4°C. The resulting supernatant was decanted and discarded. The pellet was rehomogenized in ice-cold buffer, diluted, and centrifuged as before. The final pellet was resuspended in the 10 mM Tris HC1 and held on ice for the receptor binding assay.
- tissue homogenizer setting 6, 15 sec
- somatostatin-14 2000 Ci/mmol; Amersham Corp., Arlington Heights, IL
- 50 mM HEPES 50 mM HEPES (pH 7.4) containing a test somatostatin agonist of various concentrations (e.g., 10 ⁇ n to 10 "6 ) , 10 mg/ml bovine serum albumin (fraction V) (Sigma Chemical Co., St.
- MgCl 2 5 mM
- Trasylol also known as aprotinin
- bacitracin also known as aprotinin
- phenylmethylsulphonyl fluoride (0.02 mg/ml).
- the final assay volume was 0.3 ml.
- the incubations were terminated by rapid filtration through GF/C filters (pre-soaked in 0.3% polyethylenimine for 30 min) using a Brandel filtration manifold (Brandel Research and Development Co., Gaithersburg, Maryland).
- Ki IC 5o / [1+ (LC/LEC) ]
- IC 50 is the concentration of test somatostatin agonist required to inhibit 50 percent of the specific binding of the radioligand [ 125 I-Tyr 11 ] somatostatin-14
- LC is the concentration of the radioligand (0.05 nM)
- LEC is the equilibrium dissociation constant of the radioligand (0.16 nM) .
- Ki values (nM) for the tested somatostatin agonists are shown in Table I.
- the somatostatin agonists may be tested for their ability to inhibit fibrosis. (a) Demonstration of Anti-Fibrotic Activity In Vi tro
- Rats are injected either with anti-thymocyte serum (ATS) (see S. Okuda et al., J. Clin. Invest., Vol. 86, 1990, pp. 453-462) to induce glomerulonephritis or with phosphate buffered saline (PBS) to serve as controls.
- ATS anti-thymocyte serum
- PBS phosphate buffered saline
- Test somatostatin or somatostatin agonists are added at the time of culture.
- the supernatant from the cultures is collected and stored at -70°C until assayed to determine the concentration of collagen I, transforming growth factor ⁇ -1 (TGF ⁇ -1), fibronectin containing an extra domain A (fibronectin EDA+) , and plasminogen activator inhibitor I (PAI-I) as markers of fibrotic activity.
- TGF ⁇ -1 transforming growth factor ⁇ -1
- fibronectin EDA+ fibronectin EDA+
- PAI-I plasminogen activator inhibitor I
- Culture conditions consisted of 2000 glomeruli/well in a 1 ml volume of serum free RPMI 1640 (with insulin supplementation) . The supernatant from the cultures are collected and stored at -70°C until assayed to determine the concentration of collagen I, transforming growth factor ⁇ -1 (TGF ⁇ -1), fibronectin containing an extra domain A (fibronectin EDA+) , and plasminogen activator inhibitor 1
- PHA markers of fibrotic activity.
- TGF ⁇ -1 matrix proteins mduced by TGF ⁇ -1 such as fibronectin EDA+, collagen I, PAH, and tenasin.
- ELISAs enzyme- linked immunoabsorbent assay
- PAS peripheral acid-Schiff
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP97939392A EP0938328B1 (en) | 1996-08-30 | 1997-08-27 | Method of inhibiting fibrosis with a somatostatin agonist |
AU41490/97A AU726731B2 (en) | 1996-08-30 | 1997-08-27 | Method of inhibiting fibrosis with a somatostatin agonist |
US09/254,097 US6268342B1 (en) | 1996-08-30 | 1997-08-27 | Method of inhibiting fibrosis with a somatostatin agonist |
CA002264309A CA2264309A1 (en) | 1996-08-30 | 1997-08-27 | Method of inhibiting fibrosis with a somatostatin agonist |
JP10511678A JP2001500483A (en) | 1996-08-30 | 1997-08-27 | Method of inhibiting fibrosis by somatostatin agonist |
DE69735674T DE69735674T2 (en) | 1996-08-30 | 1997-08-27 | PROCESS FOR INHIBITING FIBROSIS BY MEANS OF A SOMATOSTATIN AGONIST |
US10/935,593 US7238666B2 (en) | 1996-08-30 | 2004-09-07 | Method of inhibiting fibrosis with a somatostatin agonist |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70579096A | 1996-08-30 | 1996-08-30 | |
US08/705,790 | 1996-08-30 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US70579096A Continuation-In-Part | 1996-08-30 | 1996-08-30 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09254097 A-371-Of-International | 1997-08-27 | ||
US09/761,605 Division US6787521B2 (en) | 1996-08-30 | 2001-01-16 | Method of inhibiting fibrosis with a somatostatin agonist |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998008529A1 true WO1998008529A1 (en) | 1998-03-05 |
Family
ID=24834961
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/008999 WO1998008528A1 (en) | 1996-08-30 | 1997-05-28 | Method of inhibiting fibrosis with a somatostatin agonist |
PCT/US1997/014154 WO1998008529A1 (en) | 1996-08-30 | 1997-08-27 | Method of inhibiting fibrosis with a somatostatin agonist |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/008999 WO1998008528A1 (en) | 1996-08-30 | 1997-05-28 | Method of inhibiting fibrosis with a somatostatin agonist |
Country Status (13)
Country | Link |
---|---|
US (3) | US6268342B1 (en) |
EP (2) | EP1574219A3 (en) |
JP (2) | JP2001500483A (en) |
CN (1) | CN1229357A (en) |
AT (1) | ATE322905T1 (en) |
AU (2) | AU3215597A (en) |
CA (1) | CA2264309A1 (en) |
DE (1) | DE69735674T2 (en) |
ES (1) | ES2258282T3 (en) |
HU (1) | HUP9903918A3 (en) |
PL (1) | PL331922A1 (en) |
WO (2) | WO1998008528A1 (en) |
ZA (1) | ZA977783B (en) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999056769A2 (en) * | 1998-05-07 | 1999-11-11 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Inhibition of helicobacter pylori proliferation |
WO2000006185A2 (en) * | 1998-07-30 | 2000-02-10 | Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. | Methods of using lanreotide, a somatostatin analogue |
US6150333A (en) * | 1998-07-30 | 2000-11-21 | Biomeasure, Inc. | Methods of using a somatostatin analogue |
WO2001066140A1 (en) | 2000-03-09 | 2001-09-13 | Genzyme Corporation | Use of tgf-beta antagonists to treat or to prevent loss of renal function |
WO2002081499A2 (en) * | 2001-04-09 | 2002-10-17 | The Administrators Of The Tulane Educational Fund | Somatostatin agonists |
EP1291022A1 (en) * | 1998-07-30 | 2003-03-12 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Methods of using lanreotide, a somatostatin analogue |
US7378488B2 (en) | 2001-03-08 | 2008-05-27 | The Administrators Of The Tulane Educational Fund | Somatostatin antagonists |
EP2230252A1 (en) | 2006-03-13 | 2010-09-22 | The Johns Hopkins University | Augmentation of endothelial thromboresistance |
WO2011151782A1 (en) | 2010-06-02 | 2011-12-08 | Preglem Sa | A role for somatostatin to modulate initiation of follicular growth in the human ovary |
WO2012090997A1 (en) | 2010-12-27 | 2012-07-05 | 京都府公立大学法人 | iPS CELLS AND METHOD FOR GENERATING SAME |
WO2013100208A1 (en) | 2011-12-28 | 2013-07-04 | 京都府公立大学法人 | Normalization of culture of corneal endothelial cells |
US8540980B2 (en) | 2001-09-28 | 2013-09-24 | Tntgamble, Inc. | Delivery system for biological component |
EP2664343A2 (en) | 2008-11-17 | 2013-11-20 | Syntaxin Limited | Suppression of cancer |
EP2835053A1 (en) | 2010-03-12 | 2015-02-11 | Genzyme Corporation | Combination therapy for treating breast cancer |
EP2862867A2 (en) | 2005-10-25 | 2015-04-22 | The Johns Hopkins University | Methods and compositions for the treatment of Marfan syndrome and associated disorders |
WO2015064768A1 (en) | 2013-10-31 | 2015-05-07 | 京都府公立大学法人 | Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium |
EP3473643A1 (en) | 2008-06-12 | 2019-04-24 | Ipsen Bioinnovation Limited | Fusion proteins for use in the treatemnt of cancer |
EP3590956A1 (en) | 2008-06-12 | 2020-01-08 | Ipsen Bioinnovation Limited | Suppression of neuroendocrine diseases |
US10882903B2 (en) | 2015-05-18 | 2021-01-05 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods and compositions for treating an alphavirus infection |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998008528A1 (en) * | 1996-08-30 | 1998-03-05 | Biomeasure Incorporated | Method of inhibiting fibrosis with a somatostatin agonist |
IES990700A2 (en) * | 1999-08-18 | 2001-08-22 | Kinerton Ltd | Process to make a sustained release formulation |
WO2003016476A2 (en) * | 2001-08-14 | 2003-02-27 | Gene Logic, Inc. | Gene expression profiles in glomerular diseases |
US7189856B2 (en) * | 2001-12-28 | 2007-03-13 | Gideon Shapiro | Non-peptide somatostatin receptor ligands |
US20060234922A1 (en) * | 2002-10-31 | 2006-10-19 | Yoshiko Takayama | Remedy for corneal failure |
EP1643969A2 (en) * | 2003-07-11 | 2006-04-12 | Pro-Pharmaceuticals, Inc. | Compositions and methods for hydrophobic drug delivery |
US20050053664A1 (en) * | 2003-09-08 | 2005-03-10 | Eliezer Zomer | Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer |
EP1522311A1 (en) * | 2003-10-10 | 2005-04-13 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of somatostatin or analogs thereof for the preparation of a medicament for the regulation of ovarian follicles reserve by non menopausaled women |
EP1718146A2 (en) * | 2004-02-13 | 2006-11-08 | Pro-Pharmaceuticals, Inc. | Compositions and methods used to treat acne and candida |
WO2005082845A1 (en) * | 2004-02-27 | 2005-09-09 | Oy Juvantia Pharma Ltd | Novel therapies with somatostatin receptor agonists |
WO2005082844A1 (en) * | 2004-02-27 | 2005-09-09 | Oy Juvantia Pharma Ltd | Treatment of diseases by using a somatostatin receptor agonist |
LT2712617T (en) | 2004-03-12 | 2017-01-25 | Intercept Pharmaceuticals, Inc. | Treatment of fibrosis using Fxr ligands |
EP1773128A2 (en) * | 2004-08-02 | 2007-04-18 | Pro-Pharmaceuticals, Inc. | Compositions and methods for the enhancement of chemotherapy with microbial cytotoxins |
WO2008011216A2 (en) | 2006-05-16 | 2008-01-24 | Pro-Pharmaceuticals, Inc. | Galactose-pronged polysaccharides in a formulation for antifibrotic therapies |
FR2907682B1 (en) * | 2006-10-26 | 2012-12-07 | Vincience | COSMETIC AND / OR PHARMACEUTICAL COMPOSITION COMPRISING AS AN ACTIVE INGREDIENT AT LEAST ONE PEPTIDE AND THE USE OF THIS PEPTIDE. |
WO2009033765A2 (en) * | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
EP2399931A1 (en) * | 2010-06-22 | 2011-12-28 | Ipsen Pharma S.A.S. | New octapeptide compounds and their therapeutic use |
TWI523863B (en) | 2012-11-01 | 2016-03-01 | 艾普森藥品公司 | Somatostatin-dopamine chimeric analogs |
CN104768565B (en) | 2012-11-01 | 2017-04-26 | 益普生制药股份有限公司 | Somatostatin analogs and dimers thereof |
CA2899321C (en) | 2013-02-07 | 2021-03-09 | Ben C. Askew | Fluorinated .alpha..nu.integrin antagonists |
US9339515B2 (en) | 2013-02-20 | 2016-05-17 | Galectin Therapeutics, Inc. | Method for treatment of pulmonary fibrosis |
TWI736529B (en) | 2015-02-19 | 2021-08-21 | 美商賽氟洛生命科學公司 | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof |
US9572801B2 (en) | 2015-04-30 | 2017-02-21 | Scifluor Life Sciences, Inc. | Tetrahydronaphthyridinyl propionic acid derivatives and uses thereof |
WO2017189828A1 (en) | 2016-04-27 | 2017-11-02 | Scifluor Life Sciences, Inc. | Nonanoic and decanoic acid derivatives and uses thereof |
GB201816637D0 (en) * | 2018-10-12 | 2018-11-28 | Heptares Therapeutics Ltd | Selective somatostatin receptor agonists |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4904642A (en) * | 1985-09-12 | 1990-02-27 | The Administrators Of The Tulane Educational Fund | Therapeutic somatostatin analogs |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GR862206B (en) * | 1985-09-12 | 1986-12-31 | Univ Tulane | Therapeutic somatostatin analogs |
US4853371A (en) | 1986-06-17 | 1989-08-01 | The Administrators Of The Tulane Educational Fund | Therapeutic somatostatin analogs |
DE3822557C2 (en) | 1987-07-10 | 1998-07-02 | Ciba Geigy Ag | Medicines containing somatostatins |
GB8716324D0 (en) | 1987-07-10 | 1987-08-19 | Sandoz Ltd | Organic compounds |
KR0173119B1 (en) | 1989-04-26 | 1999-02-01 | 닐 에이. 밴스로우 | Linear somatostatin analog |
HU207104B (en) | 1991-01-25 | 1993-03-01 | Biosignal Kutato Fejlesztoe Kf | Process for producing new somatostatin analogs inhibiting tumour growth and pharmaceutical compositions comprising such compounds |
AU2092597A (en) * | 1996-03-07 | 1997-09-22 | Novartis Ag | Antiproliferative combinations, containing raf-targeted oligonucleotides and chemotherapeutic compounds |
WO1998008528A1 (en) * | 1996-08-30 | 1998-03-05 | Biomeasure Incorporated | Method of inhibiting fibrosis with a somatostatin agonist |
-
1997
- 1997-05-28 WO PCT/US1997/008999 patent/WO1998008528A1/en active Application Filing
- 1997-05-28 AU AU32155/97A patent/AU3215597A/en not_active Abandoned
- 1997-08-27 EP EP05076124A patent/EP1574219A3/en not_active Withdrawn
- 1997-08-27 AT AT97939392T patent/ATE322905T1/en not_active IP Right Cessation
- 1997-08-27 CA CA002264309A patent/CA2264309A1/en not_active Abandoned
- 1997-08-27 WO PCT/US1997/014154 patent/WO1998008529A1/en active IP Right Grant
- 1997-08-27 DE DE69735674T patent/DE69735674T2/en not_active Expired - Lifetime
- 1997-08-27 JP JP10511678A patent/JP2001500483A/en active Pending
- 1997-08-27 ES ES97939392T patent/ES2258282T3/en not_active Expired - Lifetime
- 1997-08-27 CN CN97197671A patent/CN1229357A/en active Pending
- 1997-08-27 EP EP97939392A patent/EP0938328B1/en not_active Expired - Lifetime
- 1997-08-27 US US09/254,097 patent/US6268342B1/en not_active Expired - Fee Related
- 1997-08-27 PL PL97331922A patent/PL331922A1/en unknown
- 1997-08-27 HU HU9903918A patent/HUP9903918A3/en unknown
- 1997-08-27 AU AU41490/97A patent/AU726731B2/en not_active Ceased
- 1997-08-29 ZA ZA977783A patent/ZA977783B/en unknown
-
2001
- 2001-01-16 US US09/761,605 patent/US6787521B2/en not_active Expired - Fee Related
-
2004
- 2004-09-07 US US10/935,593 patent/US7238666B2/en not_active Expired - Fee Related
-
2007
- 2007-10-11 JP JP2007265712A patent/JP2008074857A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4904642A (en) * | 1985-09-12 | 1990-02-27 | The Administrators Of The Tulane Educational Fund | Therapeutic somatostatin analogs |
Non-Patent Citations (1)
Title |
---|
ENDOCRINE JOURNAL, 1994, Vol. 41, No. 4, TSUKAMOTO et al., "Octreotide Treatment Results in the Inhibition of GH gene Expression in the Adenoma of the Patients with Acromegaly". * |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999056769A3 (en) * | 1998-05-07 | 2000-11-09 | Sod Conseils Rech Applic | Inhibition of helicobacter pylori proliferation |
WO1999056769A2 (en) * | 1998-05-07 | 1999-11-11 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Inhibition of helicobacter pylori proliferation |
AU770193B2 (en) * | 1998-07-30 | 2004-02-12 | Ipsen Pharma S.A.S. | Methods of using a somatostatin analogue |
WO2000006185A3 (en) * | 1998-07-30 | 2000-08-03 | Biomeasure Inc | Methods of using lanreotide, a somatostatin analogue |
US6150333A (en) * | 1998-07-30 | 2000-11-21 | Biomeasure, Inc. | Methods of using a somatostatin analogue |
EP1291022A1 (en) * | 1998-07-30 | 2003-03-12 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Methods of using lanreotide, a somatostatin analogue |
WO2000006185A2 (en) * | 1998-07-30 | 2000-02-10 | Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. | Methods of using lanreotide, a somatostatin analogue |
WO2001066140A1 (en) | 2000-03-09 | 2001-09-13 | Genzyme Corporation | Use of tgf-beta antagonists to treat or to prevent loss of renal function |
US7378488B2 (en) | 2001-03-08 | 2008-05-27 | The Administrators Of The Tulane Educational Fund | Somatostatin antagonists |
US7408024B2 (en) | 2001-03-08 | 2008-08-05 | The Administrators Of The Tulane Educational Fund | Somatostatin antagonists |
WO2002081499A2 (en) * | 2001-04-09 | 2002-10-17 | The Administrators Of The Tulane Educational Fund | Somatostatin agonists |
WO2002081499A3 (en) * | 2001-04-09 | 2003-05-08 | Univ Tulane | Somatostatin agonists |
AU2002256105B2 (en) * | 2001-04-09 | 2006-04-06 | The Administrators Of The Tulane Educational Fund | Somatostatin agonists |
US7312304B2 (en) | 2001-04-09 | 2007-12-25 | The Administrators Of The Tulane Educational Fund | Somatostatin agonists |
US8540980B2 (en) | 2001-09-28 | 2013-09-24 | Tntgamble, Inc. | Delivery system for biological component |
EP2862867A2 (en) | 2005-10-25 | 2015-04-22 | The Johns Hopkins University | Methods and compositions for the treatment of Marfan syndrome and associated disorders |
EP2230252A1 (en) | 2006-03-13 | 2010-09-22 | The Johns Hopkins University | Augmentation of endothelial thromboresistance |
EP3590956A1 (en) | 2008-06-12 | 2020-01-08 | Ipsen Bioinnovation Limited | Suppression of neuroendocrine diseases |
EP3473643A1 (en) | 2008-06-12 | 2019-04-24 | Ipsen Bioinnovation Limited | Fusion proteins for use in the treatemnt of cancer |
EP2664343A2 (en) | 2008-11-17 | 2013-11-20 | Syntaxin Limited | Suppression of cancer |
EP3241560A1 (en) | 2008-11-17 | 2017-11-08 | Ipsen Bioinnovation Limited | Suppression of cancer |
EP2835053A1 (en) | 2010-03-12 | 2015-02-11 | Genzyme Corporation | Combination therapy for treating breast cancer |
EP3406141A1 (en) | 2010-03-12 | 2018-11-28 | Genzyme Corporation | Combination therapy for treating cancer |
WO2011151782A1 (en) | 2010-06-02 | 2011-12-08 | Preglem Sa | A role for somatostatin to modulate initiation of follicular growth in the human ovary |
WO2012090997A1 (en) | 2010-12-27 | 2012-07-05 | 京都府公立大学法人 | iPS CELLS AND METHOD FOR GENERATING SAME |
EP3553169A1 (en) | 2011-12-28 | 2019-10-16 | Kyoto Prefectural Public University Corporation | Normalization of culture of corneal endothelial cells |
WO2013100208A1 (en) | 2011-12-28 | 2013-07-04 | 京都府公立大学法人 | Normalization of culture of corneal endothelial cells |
WO2015064768A1 (en) | 2013-10-31 | 2015-05-07 | 京都府公立大学法人 | Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium |
EP3804760A1 (en) | 2013-10-31 | 2021-04-14 | Kyoto Prefectural Public University Corporation | Therapeutic drug for diseases related to endoplasmic reticulum cell death in corneal endothelium |
US10882903B2 (en) | 2015-05-18 | 2021-01-05 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods and compositions for treating an alphavirus infection |
Also Published As
Publication number | Publication date |
---|---|
US6268342B1 (en) | 2001-07-31 |
PL331922A1 (en) | 1999-08-16 |
HUP9903918A2 (en) | 2000-04-28 |
EP0938328A1 (en) | 1999-09-01 |
HUP9903918A3 (en) | 2000-07-28 |
JP2001500483A (en) | 2001-01-16 |
DE69735674D1 (en) | 2006-05-24 |
JP2008074857A (en) | 2008-04-03 |
EP0938328A4 (en) | 2002-08-28 |
ATE322905T1 (en) | 2006-04-15 |
EP0938328B1 (en) | 2006-04-12 |
EP1574219A2 (en) | 2005-09-14 |
AU4149097A (en) | 1998-03-19 |
AU3215597A (en) | 1998-03-19 |
ZA977783B (en) | 1999-03-01 |
EP1574219A3 (en) | 2006-04-26 |
US7238666B2 (en) | 2007-07-03 |
US20010011072A1 (en) | 2001-08-02 |
ES2258282T3 (en) | 2006-08-16 |
WO1998008528A1 (en) | 1998-03-05 |
DE69735674T2 (en) | 2007-04-05 |
CN1229357A (en) | 1999-09-22 |
AU726731B2 (en) | 2000-11-16 |
US6787521B2 (en) | 2004-09-07 |
CA2264309A1 (en) | 1998-03-05 |
US20050222025A1 (en) | 2005-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6268342B1 (en) | Method of inhibiting fibrosis with a somatostatin agonist | |
AU2008284269B2 (en) | Method for inhibiting inflammation and pre-inflammatory cytokine/chemokine expression using a ghrelin analogue | |
US7662784B2 (en) | Method for decreasing body weight using a somatostatin receptor agonist | |
WO1997009060A1 (en) | Method of treating insulin resistance | |
US5686418A (en) | Prolonging survival of transplanted pancreatic cells | |
EP1075273A2 (en) | Inhibiton of helicobacter pylori proliferation | |
US6342479B1 (en) | Prolonging survival of transplanted pancreatic cells | |
EP0980253A1 (en) | Somatostatin and somatostatin agonists for treating insulin insensitivity and syndrome x | |
AU775508B2 (en) | Inhibition of abnormal cell growth with corticotropin-releasing hormone analogs | |
MXPA99001975A (en) | Method of inhibiting fibrosis with a somatostatin agonist | |
US20020151500A1 (en) | Method and compositions for treating hyperlipidemia and other conditions | |
EP0979098A1 (en) | Method of treating hyperprolactinemia and prolactinomas | |
AU2013201451B2 (en) | Method for inhibiting inflammation and pre-inflammatory cytokine/chemokine expression using a ghrelin analogue | |
WO2005080412A1 (en) | Modulators of fatty acid-stimulated insulin secretion and uses thereof | |
CA2289490A1 (en) | Method and compositions for treating hyperlipidemia and other conditions | |
EP1332762A1 (en) | Method of treating hyperprolactinemia and prolactinomas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 97197671.6 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2264309 Country of ref document: CA Ref document number: 2264309 Country of ref document: CA Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 1998 511678 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1999/001975 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997939392 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09254097 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1997939392 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1997939392 Country of ref document: EP |